Nothing Special   »   [go: up one dir, main page]

ATE556596T1 - Regulierte attenuierung von lebendimpfstoffen zur verbesserung der kreuzimmunitätsschutzfunktion - Google Patents

Regulierte attenuierung von lebendimpfstoffen zur verbesserung der kreuzimmunitätsschutzfunktion

Info

Publication number
ATE556596T1
ATE556596T1 AT03721711T AT03721711T ATE556596T1 AT E556596 T1 ATE556596 T1 AT E556596T1 AT 03721711 T AT03721711 T AT 03721711T AT 03721711 T AT03721711 T AT 03721711T AT E556596 T1 ATE556596 T1 AT E556596T1
Authority
AT
Austria
Prior art keywords
immmunity
protective function
live vaccines
improve cross
regulated attenuation
Prior art date
Application number
AT03721711T
Other languages
English (en)
Inventor
Roy Curtiss
Original Assignee
Univ St Louis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ St Louis filed Critical Univ St Louis
Application granted granted Critical
Publication of ATE556596T1 publication Critical patent/ATE556596T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36Adaptation or attenuation of cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0258Escherichia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0275Salmonella
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255Salmonella (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT03721711T 2002-04-15 2003-04-15 Regulierte attenuierung von lebendimpfstoffen zur verbesserung der kreuzimmunitätsschutzfunktion ATE556596T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37261602P 2002-04-15 2002-04-15
US37362602P 2002-04-18 2002-04-18
PCT/US2003/011802 WO2003096812A1 (en) 2002-04-15 2003-04-15 Regulated attenuation of live vaccines to enhance cross protective immunogenicity

Publications (1)

Publication Number Publication Date
ATE556596T1 true ATE556596T1 (de) 2012-05-15

Family

ID=29553427

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03721711T ATE556596T1 (de) 2002-04-15 2003-04-15 Regulierte attenuierung von lebendimpfstoffen zur verbesserung der kreuzimmunitätsschutzfunktion

Country Status (5)

Country Link
US (1) US8133493B2 (de)
EP (2) EP1499191B1 (de)
AT (1) ATE556596T1 (de)
CA (1) CA2526895A1 (de)
WO (1) WO2003096812A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8337861B2 (en) * 2003-01-09 2012-12-25 The Trustees Of The University Of Pennsylvania Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
CA2522689A1 (en) * 2003-04-18 2004-10-28 Warnex Research Inc. Oligonucleotides for the detection of salmonella species
CN101522210B (zh) 2006-09-18 2017-03-22 阿肯色大学评议会 增强免疫应答的组合物和方法
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
WO2009025888A2 (en) 2007-05-10 2009-02-26 The Arizona Board Of Regents For And On Behalf Of Arizona State University Regulated synthesis of antigen and/or regulated attentuation to enhance vaccine immunogenics and/or safety
EP2152883A4 (de) * 2007-05-10 2010-10-27 Univ Arizona Rekombinante bakterien mit vektoren zur expression von nukleinsäuresequenzencodierenden antigenen
CN101903399B (zh) * 2007-06-08 2014-09-10 澳大利亚家禽Crc私人有限公司 梭菌毒素netb
US20090035815A1 (en) * 2007-06-29 2009-02-05 Laxmi Srinivas Rao Synthetic Gene for Enhanced Expression in E. Coli
US8465755B2 (en) 2007-10-05 2013-06-18 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against enteric pathogens
WO2009059018A1 (en) * 2007-10-30 2009-05-07 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
NZ601880A (en) 2007-11-01 2013-12-20 Univ Arkansas Compositions and methods of enhancing immune responses to eimeria
WO2010045620A1 (en) * 2008-10-17 2010-04-22 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae
WO2010094699A1 (en) * 2009-02-19 2010-08-26 Creatogen Laboratories Gmbh Attenuated salmonella enteritidis strain
US9163219B2 (en) * 2009-04-14 2015-10-20 Arizona Board Of Regents On Behalf Of Arizona State University Single expression vector for generation of a virus with a segmented genome
US8709444B2 (en) 2009-05-14 2014-04-29 Northwestern University Live-attenuated compositions for bacterial infections
GB2483595B (en) 2009-05-22 2017-03-29 The Arizona Board Of Regents For And On Behalf Of Arizona State Univ Recombinant bacterium and methods of antigen and nucleic acid delivery
US9045742B2 (en) 2009-05-29 2015-06-02 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant Edwardsiella bacterium
US9062297B2 (en) 2010-01-13 2015-06-23 The Arizona Board Of Regents For And On Behalf Of Arizona State University Yersinia pestis vaccine
KR101638661B1 (ko) 2010-01-21 2016-07-11 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 백신 벡터 및 면역 반응을 강화시키는 방법
US8889121B2 (en) 2010-01-22 2014-11-18 The Arizona Board Of Regents For An On Behalf Of Arizona State University Bacterium comprising a regulated rfaH nucleic acid
WO2011150421A2 (en) 2010-05-28 2011-12-01 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium to decrease tumor growth
BR112012031211A2 (pt) 2010-06-09 2018-01-30 Univ Arkansas métodos e vacina para reduzir a infecção causada pelo campylobacter
US9255283B2 (en) 2010-07-02 2016-02-09 The Arizona Board Of Regents For And On Behalf Of Arizona State University Compositions and methods for bacterial lysis and neutral lipid production
WO2013116639A1 (en) 2012-02-01 2013-08-08 Arizona Board Of Regents On Behalf Of The University Of Arizona Campylobacter immunogenic compositions and uses thereof
US9303264B2 (en) 2012-05-18 2016-04-05 The Arizona Board Of Regents For And On Behalf Of Arizona State University Photosynthetic microorganisms expressing thermostable lipase
AU2014216246B2 (en) 2013-02-14 2018-12-20 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to Eimeria or limiting Eimeria infection
MY173901A (en) 2013-03-15 2020-02-26 Texas A & M Univ Sys Compositions and methods of enhancing immune responses to enteric pathogens
US9580718B2 (en) 2013-06-17 2017-02-28 Arizona Board Of Regents On Behalf Of Arizona State University Attenuated live bacteria with increased acid resistance and methods of use thereof
US9868769B2 (en) 2014-01-06 2018-01-16 The United States Of America, As Represented By The Secretary Of Agriculture Mutated Salmonella enteriaca
EP3122773B1 (de) * 2014-03-27 2020-07-22 Ghosh, Sambuddha Expression eines einkettigen antikörpers gegen salmonellen in lactobacillus
SG11201809686SA (en) 2016-05-03 2018-11-29 Univ Arkansas Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
JP7097438B2 (ja) 2017-07-11 2022-07-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
CN112673092B (zh) 2018-07-11 2024-03-29 阿克蒂姆治疗有限公司 工程化的免疫刺激性细菌菌株及其用途
US11242528B2 (en) 2018-08-28 2022-02-08 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
EP4142781A4 (de) * 2020-04-30 2024-09-04 University Of Florida Research Foundation, Incorporated Lebende selbstzerstörende bakterielle adjuvantien zur erhöhung der immunitätsinduktion
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN112695004A (zh) * 2020-12-28 2021-04-23 南通大学 APEC双基因rpoS和arcA缺失菌株及弱毒疫苗
WO2022271976A1 (en) * 2021-06-24 2022-12-29 Elanco Us Inc. Attenuated salmonella, vaccines, and delivery platform

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888170A (en) 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5294441A (en) 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
AU637969B2 (en) 1987-10-07 1993-06-17 Washington University A method of maintaining a desired recombinant gene in a genetic population of cells
AU645489B2 (en) 1989-03-31 1994-01-20 Washington University Vaccines containing avirulent phoP-type microorganisms
GB8912330D0 (en) * 1989-05-30 1989-07-12 Wellcome Found Live vaccines
ATE167061T1 (de) * 1989-11-03 1998-06-15 Univ Washington Kreuzschützende salmonella impfstoffe
ATE173166T1 (de) 1992-09-04 1998-11-15 Univ Saskatchewan Neue bakterielle impfstoffe unter verwendung von impfstämmen von pathogenen bakterien
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
US6024961A (en) * 1997-11-14 2000-02-15 Washington University Recombinant avirulent immunogenic S typhi having rpos positive phenotype
EP1064366A1 (de) * 1998-03-20 2001-01-03 Human Genome Sciences, Inc. Gene und polypeptide von staphylococcus aureus.
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6713073B1 (en) 1998-07-24 2004-03-30 Megan Health, Inc. Method of vaccination of newly hatched poultry
US6399074B1 (en) * 1998-07-24 2002-06-04 Megan Health, Inc. Live attenuated salmonella vaccines to control avian pathogens
US6780405B1 (en) * 2000-04-28 2004-08-24 Avant Immunotherapeutics, Inc. Regulated antigen delivery system (RADS)

Also Published As

Publication number Publication date
EP2380440B1 (de) 2016-03-09
EP1499191A4 (de) 2006-06-21
WO2003096812A1 (en) 2003-11-27
EP1499191B1 (de) 2012-05-09
CA2526895A1 (en) 2003-11-27
US8133493B2 (en) 2012-03-13
EP1499191A1 (de) 2005-01-26
AU2003235457A1 (en) 2003-12-02
EP2380440A1 (de) 2011-10-26
US20060233829A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
ATE556596T1 (de) Regulierte attenuierung von lebendimpfstoffen zur verbesserung der kreuzimmunitätsschutzfunktion
ECSP11010975A (es) Método de uso de una cepa de bacillus subtilis para mejorar la salud de animales
DE60039198D1 (de) Adjuvanszusammensetzungen zur Erhöhung der Immunantwort bezüglich Polynukleotid-basierenden Impfstoffen
ATE451119T1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
ATE426412T1 (de) Adjuvante influenza-vakzine
MY149604A (en) C.perfringens alpha toxoid vaccine
NO20025590D0 (no) Fenylglycin-derivater
ECSP077179A (es) Co-cultivos manejados de organismos que tienen efectos profilacticos y promotores de la salud
HUP0301634A2 (hu) Hőmérséklet-érzékeny, élő vakcina Mycoplasma hyopneumoniaera
ME01140B (me) Virus goveđe virusne dijareje s modifikovanim erns proteinom
GB2386072A (en) Novel vaccine
BR0316346A (pt) Vacina para vìrus do nilo ocidental
MX2010000864A (es) Vacuna de celulas enteras estafilococcicas inactivadas.
PT1112747E (pt) Vacina de salmonella que nao induz anticorpos contra flagelina ou flagelos
ATE419008T1 (de) Adjuvante zusammensetzung und anwendungsverfahren dafür
DK1395283T3 (da) Heterolog beskyttelse induceret ved immunisering med Invaplex-vaccine
RS52188B (en) A PSYCHI VACCINE FOR THE PROTECTION OF ERLIHIOSIS
ATE521621T1 (de) Cpg-einzelstrang-desoxynukleotide zur verwendung als adjuvans
DE69824794D1 (de) Streptococcus equi Impfstoff
ATE359815T1 (de) Streptococcus-phocae-vakzine
TW200503755A (en) Avian vaccine composition for the protection of poultry against disease and infection caused by e. coli and salmonella
SG147465A1 (en) Vaccine
DK1074266T3 (da) Levende svækkede bakterier til anvendelse i vaccine
AR041090A1 (es) Uso de toxina labil al calor de esterichia coli como adyuvante en pajaros y aves de corral
HUP9700975A2 (hu) Élő, legyengített, Pasteurellaceae családba tartozó, RTX-termelő baktériumok